Arthneeti
VO

Valiant Organics Ltd

Q1 FY27Chemicals & Petrochemicals

Valiant Organics Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.

Price₹411
Market cap₹1.2K Cr
P/E23.7
Updated24 Sept 2026
Read4 min read

Based on Valiant Organics Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Revenue from Operations for Q1-FY27: INR 2,315 million - Year-on-year (YoY) growth in Revenue: 13.3% increase from INR 2,044 million in Q1-FY26 (Page 13, 12) - Total Revenue reported as INR 2,342 million for Q1-FY27 with 14% YoY growth (Page 10) - Sales volumes by chemistry for Q1-FY27 (metric tons): - Chlorination: approx. Q1-FY27 EBITDA: INR 416 million - EBITDA Margin: 17.97% - Year-on-Year EBITDA Growth: 67.7% (from INR 248 million in Q1-FY26) - EBITDA Margin Increase: +584 basis points YoY

From Valiant Organics Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Revenue from Operations for Q1-FY27: INR 2,315 million
  • Year-on-year (YoY) growth in Revenue: 13.3% increase from INR 2,044 million in Q1-FY26 (Page 13, 12)
  • Total Revenue reported as INR 2,342 million for Q1-FY27 with 14% YoY growth (Page 10)
  • Sales volumes by chemistry for Q1-FY27 (metric tons):
  • Chlorination: approx. 440 MT
  • Hydrogenation: approx. 478 MT
  • Ammonolysis: approx. 513 MT

2 more points management made on revenue & sales performance

Profitability & Margins

See what Valiant Organics Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The investor presentation does not explicitly mention any ongoing or planned capex, capacity expansions, or new plants/projects with specific amounts, status, or timelines. It provides: - Manufacturing footprint details with existing capacities for various chemistries and locations but no planned expansions. - Operational and financial highlights focused on current production and performance. - No direct references to capex amounts, new projects, expansions, or timelines within the provided pages. Thus, based solely on the presentation content, no capex or capacity expansion initiatives are described.

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

5x potential
1Shiv Texchem
Rev 1Mar 2
2Yasho Industries
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Valiant Organics Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation for Valiant Organics Limited does not explicitly report or provide specific figures related to: - Order book - Order inflow - Pending orders No section or slide in the presentation mentions these metrics directly or provides quantitative data on current or future orders. The presentation focuses primarily on financial performance, operational highlights, product segmentation, and company strengths without detailing order backlog or inflow information.

Valiant Organics Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹218 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Valiant Organics Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Prasol Chemicals Ltd (Q1 FY27)

    Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank

  • Vipul Organics Ltd (Q1 FY27)

    Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…

  • Fine Organic Industries Ltd (Q1 FY27)

    Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

  • Chemfab Alkalis Ltd (Q1 FY27)

    Consolidated Q1FY27 Revenue from Operations:** ₹73.16 crore, down 20.08% YoY (from ₹91.54 crore in Q1FY26). Key concall takeaways from Chemfab Alkalis Ltd's Q1…

Compare:vs Solar Industriesvs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Valiant Organics Ltd Q1 FY27 results?

Revenue from Operations for Q1-FY27: INR 2,315 million - Year-on-year (YoY) growth in Revenue: 13.3% increase from INR 2,044 million in Q1-FY26 (Page 13, 12) - Total Revenue reported as INR 2,342 million for Q1-FY27 with 14% YoY growth (Page 10) - Sales volumes by chemistry for Q1-FY27 (metric tons): - Chlorination: approx. Q1-FY27 EBITDA: INR 416 million - EBITDA Margin: 17.97% - Year-on-Year EBITDA Growth: 67.7% (from INR 248 million in Q1-FY26) - EBITDA Margin Increase: +584 basis points YoY

What is Valiant Organics Ltd share price analysis?

Valiant Organics Ltd currently shows a neutral. The stock trades at a P/E of 23.7 with a market cap of ₹1,196 Cr. Investors should review the full earnings analysis for detailed insights.

Is Valiant Organics Ltd planning capital expenditure?

The investor presentation does not explicitly mention any ongoing or planned capex, capacity expansions, or new plants/projects with specific amounts, status, or timelines.

Keep Valiant Organics Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.